TriSalus Life Sciences (NASDAQ:TLSI) Raised to “Strong-Buy” at Northland Capmk

Northland Capmk upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) to a strong-buy rating in a report issued on Friday morning, Zacks.com reports.

A number of other research analysts have also recently commented on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $12.00 price target on shares of TriSalus Life Sciences in a research report on Thursday, June 27th. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, Northland Securities began coverage on shares of TriSalus Life Sciences in a research note on Friday. They issued an “outperform” rating and a $12.50 price target for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $12.50.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI opened at $4.07 on Friday. TriSalus Life Sciences has a 52-week low of $3.32 and a 52-week high of $10.42. The company has a fifty day moving average of $4.74 and a 200-day moving average of $6.43. The company has a market capitalization of $119.29 million, a P/E ratio of -1.63 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million during the quarter. As a group, analysts forecast that TriSalus Life Sciences will post -1.53 EPS for the current fiscal year.

Insider Transactions at TriSalus Life Sciences

In other news, CEO Mary T. Szela purchased 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Duquesne Family Office LLC increased its stake in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Highbridge Capital Management LLC bought a new stake in TriSalus Life Sciences in the second quarter valued at $1,184,000. Finally, Wolverine Asset Management LLC purchased a new position in TriSalus Life Sciences during the 2nd quarter valued at $240,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.